Sipa-Gene and Sipa-1 Inhibitor for the Diagnosis and Treatment of Metastatic Cancer
Description of Invention:
This technology relates to methods and compositions of a new gene Sipa-1 that can identify and treat metastatic cancer. The inventors have identified the Sipa-1 gene as a possible metastasis modifying gene. Further analyses revealed that Sipa-1 expression levels correlate with metastasis. Inhibitors that modulate the Sipa-1 expression and reduce metastasis in animal models have been identified. Additionally, single nucleotide polymorphisms (SNPs) present in the mouse Sipa-1 gene have been identified that, if also present in humans, could serve as the basis for diagnosing cancer and metastasis.
Market Opportunity:
No screening markers are currently available in the market that can diagnose early metastasis, which causes majority of cancer related deaths. Opportunity for new diagnostic and therapeutic technologies exists as personalized medicine is taking a major role in the clinical management of cancer. This invention can provide the much needed new diagnostic marker for predicting early metastasis as well as a new therapy targeting metastasis causing factors.
Applications and Modality:
Method for diagnosing early onset of metastasis with Sipa-1.
Sipa-1 as a new therapeutic target for treatment of metastatic cancer.
Advantages:
Simple PCR based assay for detecting single nucleotide polymorphisms (SNPs) within the Sipa-1 gene.
Inhibitors of Sipa-1 are known in the art, they can be easily screened from existing small molecule libraries.
Current Development Status:
The technology is currently in the pre-clinical stage of development.
Proof of concept results show that inhibition of Sipa-1 reduces metastasis in mouse models.
Laboratory data shows single nucleotide polymorphisms (SNPs) within the Sipa-1 gene linked to metastatic disease.
Related Technologies: DHHS Reference No. E-216-2005/0 --
U.S. Provisional Application No. 60/695,024 filed 29 Jun 2005
Relevant Publication:
PCT Publication No. WO 2006084027, published October 8, 2006.
YG Park et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet. 2005 Oct;37(10):1055-1062. Epub 2005 Sep 4. [PubMed abs]
NP Crawford et al. Germline polymorphisms in SIPA-1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res. 2006;8(2):R16. Epub 2006 Mar 21. [PubMed abs]
Licensing Status: Available for exclusive and non-exclusive licensing.
Portfolios: Cancer
Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
